Arsenic exposure is a worldwide environmental health problem causing multiple chronic diseases including
cancer. Cancer results from mutations in, and epigenetic modifications of, oncogenes and tumor suppressor
genes. The molecular mechanisms driving arsenic (iAs)-inducedcarcinogenesis are likely a complex interplay
of multiple factors contributing to yet unidentified genetic changes responsible for tumorigenesis. One
mechanism is the epigenetic effect of miRNA dysregulation. iAs-exposure induces chromosomal instability
(CIN) and CIN contributes to carcinogenesis. We focused on mechanism and effects of overexpression of hsa-
miR-186 on CIN in the previous funding period. miR-186 is an intronic miRNA and is overexpressed in iAs-
induced squamous cell carcinoma (SCC). The parent gene encodes an alternative mRNA splicing factor that
is disrupted by iAs-exposure. miR-186 overexpression in human keratinocytes suppresses two mitotic
regulators and gives rise to aneuploidy, a hallmark of cancer. This investigation led to establishment of a new
human keratinocyte model for iAs-inducedcarcinogenesis using Ker-CT cells that is more amenable to
karyotype analysis necessary to analyze CIN for leads into carcinogenic mutations. We identified 5 additional
miRNAs that are overexpressed in iAs-induced SCC and also in human keratinocytes (HaCaT) chronically
exposed to low dose iAs. These miRNAs are predicted to target multiple proteins also targeted by known
oncogenic miRNAs. This continuation application focuses on miRNAs dysregulated in iAs-induced SCC and
proposes to identify additional miR-186 targets contributing to CIN and to characterize the impact of the
additional 5 overexpressed miRNAs on carcinogenesis. The hypothesis underlying these studies is that
dysregulation of RNA metabolism contributes to iAs-inducedcarcinogenesis by modulating gene expression
and inducing CIN. The specific aims are: 1) Determine the mechanism of hsa-miR-186 overexpression
inducing aneuploidy and CIN in new Ker-CT model; 2) Characterize the new Ker-CT model of iAs-induced skin
carcinogenesis; 3) Investigate role in cellular transformation of miRNAs common to SCC and arsenite-exposed
HaCaT cells. Mutations in cancer genes in cells transformed by miR-186 overexpression and arsenic
exposure will be characterized providing information to fill a knowledge gap. Demonstrating that these miRNAs
overexpressed in human iAs-induced SCC share targets with known oncogenic miRNAs will establish an
epigenetic mechanism and be a major step forward in our understanding of the mechanism of iAs-inducedcarcinogenesis, thus filling a critical knowledge gap in our understanding. The principles learned will provide a
translational framework for understanding the molecular mechanisms operative in iAs-inducedcarcinogenesis
in other tissues and cell types. Identification of mutations in, or epigenetic silencing of, cancer genes induced
by iAs exposure will be a major step forward in our understanding of the mechanism of iAs-inducedcarcinogenesis.
Public Health Relevance Statement
Narrative
Some microRNAs can act as oncogenes or tumor suppressors by suppressing the expression of tumor
suppressor or oncogene proteins. The proposed studies will determine whether microRNAs overexpressed in
skin cancers caused by chronic arsenic exposure contribute to the development of skin cancer by targeting
proteins in common with known oncogenic microRNAs.
National Institute of Environmental Health Sciences
CFDA Code
113
DUNS Number
057588857
UEI
E1KJM4T54MK6
Project Start Date
01-August-2017
Project End Date
30-November-2028
Budget Start Date
23-January-2024
Budget End Date
30-November-2024
Project Funding Information for 2024
Total Funding
$662,892
Direct Costs
$425,000
Indirect Costs
$237,892
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Environmental Health Sciences
$662,892
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2R01ES027778-06A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01ES027778-06A1
Patents
No Patents information available for 2R01ES027778-06A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01ES027778-06A1
Clinical Studies
No Clinical Studies information available for 2R01ES027778-06A1
News and More
Related News Releases
No news release information available for 2R01ES027778-06A1
History
No Historical information available for 2R01ES027778-06A1
Similar Projects
No Similar Projects information available for 2R01ES027778-06A1